Clinical Trials Browser

Low Grade Serous Ovarian Cancer

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Gynecologic

Endometrial Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

720 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03624244 2026-02-17

BFR-ESS

Phase 2 Recruiting

40 enrolled

Gynecologic

Endometrial Stromal Tumors

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Phase 2 Recruiting

32 enrolled

Gynecologic

Endometrial Neoplasms

NCT06394804 2026-02-03

CHAMELEON

Phase 2 Recruiting

20 enrolled

Gynecologic

Low-Grade Serous Ovarian Cancer

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04111978 2025-09-29

MATAO

Phase 3 Recruiting

540 enrolled

Gynecologic

Fallopian Tube Neoplasms, Peritoneal Neoplasms

NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Phase 2/3 Recruiting

80 enrolled

Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Phase 2/3 Recruiting

29 enrolled

GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Phase 2 Recruiting

32 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Phase 2 Recruiting

180 enrolled

Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT05247268 2025-04-06

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Phase 2 Recruiting

104 enrolled

Gynecologic

Endometrial Neoplasms

NCT05872204 2025-03-19

ALEPRO

Phase 2 Recruiting

100 enrolled

Gynecologic

Low Grade Serous Ovarian Carcinoma

NCT05601700 2025-01-27

LEPRE

Phase 3 Recruiting

132 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

Clinical Trials

RAMP 301

EndoMAP

FEMUS

PIKALO-1

BFR-ESS

ALPINE: Maintenance Letrozole/Abemaciclib

CHAMELEON

Study of AVZO-021 in Patients With Advanced Solid Tumors

MATAO

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

ALEPRO

LEPRE